Clinical Report: Implications of Delaying BCG Vaccination in SCID Patients

Overview

The postponement of BCG vaccination from birth to 6 months in Saudi Arabia has led to a significant reduction in BCG-related complications among patients with severe combined immunodeficiency (SCID), decreasing BCGitis from 46.1% to 2.6%.

Background

BCG vaccination is crucial in preventing severe forms of tuberculosis (TB) in pediatric populations, especially in TB-endemic regions. In Saudi Arabia, the Ministry of Health's decision to delay BCG vaccination has been reported, but the impact on the general neonatal population remains unclear.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• The postponement of BCG vaccination resulted in a decrease in BCGitis among SCID patients from 46.1% to 2.6% (p < 0.001).
• The study focused solely on SCID patients without assessing the impact on the general neonatal population.
• Saudi Arabia's TB incidence is approximately 8.4 per 100,000.
• The study did not compare the 6-month delay with the internationally adopted 28-day vaccination model.
• There was no assessment of BCG coverage rates or defaulter rates following the policy change.
• Non-specific protective effects of neonatal BCG vaccination were not considered in the study.

Clinical Implications

The findings highlight the need for careful consideration of vaccination policies that balance the risks of BCG-related complications in SCID patients with the need for TB protection in the broader population. Ongoing evaluation of vaccination strategies is essential to ensure optimal health outcomes.

Conclusion

While the delay in BCG vaccination has reduced complications in SCID patients, the broader implications for public health and vaccination policy require further investigation.

Related Resources & Content

1. Aldhaheri A et al., Front. Immunol., 2025 -- The effects of postponing BCG vaccination on the risk of BCG-related complications among patients with severe combined immunodeficiency disease in Saudi Arabia
2. WHO, WHO position paper – February 2018 -- BCG vaccines: WHO position paper
3. ScienceDirect, BCG vaccination in patients with severe combined immunodeficiency -- Complications, risks, and vaccination policies
4. Open Forum Infectious Diseases — Evaluating the Safety of Bacillus Calmette-Guérin Vaccination and Its Effects on HIV-1 Latent Reservoir in Individuals with Treated HIV-1 Infection
5. The Journal of Infectious Diseases — Does Systemic Spread of BCG After Neonatal Vaccination Enhance Protection Against Mycobacterium tuberculosis?
6. Infection — Comparative Analysis of Immunogenic Responses to Two Hepatitis B Vaccination Regimens
7. Bone Marrow Transplantation — Worsening of Chronic Graft-Versus-Host Disease Following SARS-CoV-2 Vaccination
8. Evaluating the Safety of Bacillus Calmette-Guérin Vaccination and Its Effects on HIV-1 Latent Reservoir in Individuals with Treated HIV-1 Infection
9. Does Systemic Spread of BCG After Neonatal Vaccination Enhance Protection Against Mycobacterium tuberculosis?
10. BCG vaccines: WHO position paper – February 2018 – Vaccins BCG: Note de synthèse de l’OMS – Février 2018
11. BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies - ScienceDirect
12. Frontiers | The effects of postponing BCG vaccination on the risk of BCG-related complications among patients with severe combined immunodeficiency disease in Saudi Arabia